Менопауза и преждевременная недостаточность яичников при ревматических заболеваниях

Паневин Т.С., Ледина А.В., Зоткин Е.Г. Менопауза и преждевременная недостаточность яичников при ревматических заболеваниях. Гинекология. 2023;25(4):428–434. DOI: 10.26442/20795696.2023.4.202366

© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.

________________________________________________

Panevin TS, Ledina AV, Zotkin EG. Menopause and premature ovarian insufficiency in rheumatic diseases: A review. Gynecology. 2023;25(4):428–434. DOI: 10.26442/20795696.2023.4.202366

Читать PDF

Аннотация

Преждевременная недостаточность яичников (ПНЯ) – это клинический синдром, определяемый как потеря функции яичников в возрасте до 40 лет. Среди причин ПНЯ – генетические, обменные нарушения, а также инфекционный или ятрогенный факторы, однако в ряде случаев точную причину установить не удается. Учитывая возможную ассоциацию недостаточности яичников с аутоиммунными нарушениями, а также обнаружение антител к нормальной ткани яичников в сыворотке крови пациенток с ПНЯ, предполагается, что аутоиммунный механизм является значимой причиной синдрома. Принимая во внимание взаимосвязь между ПНЯ и аутоиммунными заболеваниями, представляется актуальным освещение вопросов взаимовлияния овариальной функции женщин с ПНЯ и ревматических заболеваний (в частности, системной красной волчанки, ревматоидного артрита и системной склеродермии), что представлено в обзоре. Заместительная гормональная терапия может быть рекомендована женщинам с ПНЯ для повышения качества их жизни.

Ключевые слова: преждевременная недостаточность яичников, менопауза, антиовариальные антитела, системная красная волчанка, ревматоидный артрит, системная склеродермия, ревматические заболевания, заместительная гормональная терапия

________________________________________________

Premature ovarian insufficiency (POI) is a clinical syndrome defined as loss of ovarian function before the age of 40 years. Among the causes of POI are genetic, metabolic disorders, as well as infectious or iatrogenic factors, but in some cases the exact cause cannot be established. Given the possible association of ovarian failure with autoimmune disorders, as well as the detection of antibodies to normal ovarian tissue in the serum of patients with POI, it is assumed that an autoimmune mechanism is a significant cause of the syndrome. Taking into account the relationship between POI and autoimmune diseases, it seems relevant to address the issues of mutual influence of the ovarian function of women with POI and rheumatic diseases (in particular, systemic lupus erythematosus, rheumatoid arthritis and systemic scleroderma), which is presented in this review. Hormone replacement therapy may be recommended for women with POI to improve their quality of life.

Keywords: premature ovarian insufficiency, menopause, anti-ovarian antibodies, systemic lupus erythematosus, rheumatoid arthritis, systemic scleroderma, rheumatic diseases, hormone replacement therapy

Полный текст

Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI; Webber L, Davies M, Anderson R, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926-37. DOI:10.1093/humrep/dew027
2. Адамян Л.В., Пивазян Л.Г., Антонова А.А. Преждевременная недостаточность яичников и аутоиммунитет: есть ли взаимосвязь? Проблемы репродукции.
2022;28(6):116-24 [Adamyan LV, Pivazyan LG, Antonova AA. Autoimmunity and premature ovarian insufficiency – up-to-date. Russian Journal of Human Reproduction. 2022;28(6):116-24 (in Russian)]. DOI:10.17116/repro202228061116
3. Chon SJ, Umair Z, Yoon MS. Premature Ovarian Insufficiency: Past, Present, and Future. Front Cell Dev Biol. 2021;9:672890. DOI:10.3389/fcell.2021.672890
4. Адамян Л.В., Андреева Е.Н., Артымук H.В., и др. Аменорея и олигоменорея. Клинические рекомендации. М.: Российское общество акушеров-гинекологов, 2021 [Adamian LV, Andreeva EN, Artymuk NV, et al. Amenoreia i oligomenoreia. Klinicheskiie rekomendatsii. Moscow: Rossiiskoie obshchestvo akusherov-ginekologov, 2021 (in Russian)].
5. Кравченко Е.Н., Воронцова М.С. Преждевременная недостаточность яичников, современный взгляд на проблему. Мать и дитя в Кузбассе. 2022;88(1):4-10 [Kravchenko EN, Vorontsova MS. Premature ovarian insufficiency: modern view of the problem. Mat’ i ditia v Kuzbasse. 2022;88(1):4-10 (in Russian)]. DOI:10.24412/2686-7338-2022-1-4-10
6. Ishizuka B. Current Understanding of the Etiology, Symptomatology, and Treatment Options in Premature Ovarian Insufficiency (POI). Front Endocrinol (Lausanne). 2021;12:626924. DOI:10.3389/fendo.2021.626924.
7. Christin-Maitre S, Givony M, Albarel F, et al. Position statement on the diagnosis and management of premature/primary ovarian insufficiency (except Turner Syndrome). Ann Endocrinol (Paris). 2021;82(6):555-71. DOI:10.1016/j.ando.2021.09.001.
8. Адамян Л.В., Пивазян Л.Г. Междисциплинарный подход и современное состояние вопроса о преждевременном старении яичников (обзор литературы). Проблемы репродукции. 2023;29(1):94-103 [Adamyan LV, Pivazyan LG. Interdisciplinary approach and the current state of the issue of premature ovarian aging (literature review). Russian Journal of Human Reproduction. 2023;29(1):94-103 (in Russian)]. DOI:10.17116/repro20232901194
9. Андреева Е.Н., Абсатарова Ю.С., Ахматова Р.Р., и др. Преждевременная недостаточность яичников: от основ патогенеза к перспективам в лечении. Вопросы гинекологии, акушерства и перинатологии. 2021;20(5):100-7 [Andreeva EN, Absatarova YS, Akhmatova RR, et al. Primary ovarian insufficiency: from basis of pathogenesis to treatment perspectives. Gynecology, Obstetrics and Perinatology. 2021;20(5):100-7 (in Russian)]. DOI:10.20953/1726-1678-2021-5-100-107
10. Forges T, Monnier-Barbarino P, Faure GC, Béné MC. Autoimmunity and antigenic targets in ovarian pathology. Hum Reprod Update. 2004;10(2):163-75. DOI:10.1093/humupd/dmh014
11. Domniz N, Meirow D. Premature ovarian insufficiency and autoimmune diseases. Best Pract Res Clin Obstet Gynaecol. 2019;60:42-55. DOI:10.1016/j.bpobgyn.2019.07.008.
12. Euthymiopoulou K, Aletras AJ, Ravazoula P, et al. Antiovarian antibodies in primary Sjogren's syndrome. Rheumatol Int. 2007;27(12):1149-55. DOI:10.1007/s00296-007-0364-z
13. Szeliga A, Calik-Ksepka A, Maciejewska-Jeske M, et al. Autoimmune Diseases in Patients with Premature Ovarian Insufficiency – Our Current State of Knowledge. Int J Mol Sci. 2021;22(5):2594. DOI:10.3390/ijms22052594
14. Паневин Т.С., Молашенко Н.В., Трошина Е.А., Головенко Е.Н. Аутоиммунный полигландулярный синдром взрослых: современные представления о предикторах развития поражения миокарда и диагностике компонентов заболевания. Клиническая и экспериментальная тиреоидология. 2018;14(2):92-9 [Panevin TS, Molashenko NV, Troshina EA, Golovenko EN. Autoimmune polyglandular syndrome of adults: current ideas about predictors development of damage of a myocardium and diagnostics of components of a disease. Clinical and Experimental Thyroidology. 2018;14(2):92-9 (in Russian)]. DOI:10.14341/ket9641
15. Zhen X, Qiao J, Li R, et al. Serologic autoimmunologic parameters in women with primary ovarian insufficiency. BMC Immunol. 2014;15:11. DOI:10.1186/1471-2172-15-11
16. Mignot MH, Schoemaker J, Kleingeld M, et al. Premature ovarian failure. I: The association with autoimmunity. Eur J Obstet Gynecol Reprod Biol. 1989;30(1):59-66. DOI:10.1016/0028-2243(89)90094-4
17. Власова Г.А., Перминова С.Г., Кошелева Н.М., Веюкова М.А. Влияние терапии иммуновоспалительных ревматических заболеваний на репродуктивную функцию. Акушерство и гинекология. 2021;7:53-60 [Vlasova GA, Perminova SG, Kosheleva NM, Veyukova MA. Impact of therapy for autoimmune rheumatic diseases on reproductive function. Obstetrics and Gynecology. 2021;7:53-60 (in Russian)]. DOI:10.18565/aig.2021.7.53-60
18. Перминова С.Г., Власова Г.А., Кошелева Н.М. Репродуктивная функция у женщин с ревматоидным артритом: влияние заболевания и терапии метотрексатом на уровень антимюллерова гормона. Акушерство и гинекология. 2020;4:104-10 [Perminova SG, Vlasova GA, Kosheleva NM. Reproductive function of women with rheumatoid arthritis: the effect of the disease and methotrexate therapy on the serum level of anti-Müllerian hormone. Obstetrics and Gynecology. 2020;4:104-10 (in Russian)]. DOI:10.18565/aig.2020.4.104-110
19. Алекберова З.С., Егорова О.Н., Голоева Р.Г., Черкасова М.В. Антиммюллеров гормон при системной красной волчанке. Современная ревматология. 2021;15(1):105-10 [Alekberova ZS, Egorova ON, Goloeva RG, et al. Anti-Mullerian hormone in systemic lupus erythematosus. Modern Rheumatology Journal. 2021;15(1):105-10 (in Russian)]. DOI:10.14412/1996-7012-2021-1-105-110
20. Grossmann B, Saur S, Rall K, et al. Prevalence of autoimmune disease in women with premature ovarian failure. Eur J Contracept Reprod Health Care. 2020;25(1):72-5. DOI:10.1080/13625187.2019.1702638
21. Pasoto SG, Viana VS, Mendonca BB, et al. Anti-corpus luteum antibody: a novel serological marker for ovarian dysfunction in systemic lupus erythematosus? J Rheumatol. 1999;26(5):1087-93.
22. Karakus S, Sahin A, Durmaz Y, et al. Evaluation of ovarian reserve using anti-müllerian hormone and antral follicle count in Sjögren's syndrome: Preliminary study. J Obstet Gynaecol Res. 2017;43(2):303-7. DOI:10.1111/jog.13216
23. Henes M, Froeschlin J, Taran FA, et al. Ovarian reserve alterations in premenopausal women with chronic inflammatory rheumatic diseases: impact of rheumatoid arthritis, Behçet's disease and spondyloarthritis on anti-Müllerian hormone levels. Rheumatology (Oxford). 2015;54(9):1709-12. DOI:10.1093/rheumatology/kev124
24. Brouwer J, Dolhain RJ, Hazes JM, et al. Reduced Ovarian Function in Female Rheumatoid Arthritis Patients Trying to Conceive. ACR Open Rheumatol. 2019;1(5):327-35. DOI:10.1002/acr2.11043
25. Eudy AM, McDaniel G, Hurd WW, Clowse ME. Fertility and Ovarian Reserve among Women with Rheumatoid Arthritis. J Rheumatol. 2019;46(5):455-9. DOI:10.3899/jrheum.180176
26. Giambalvo S, Garaffoni C, Silvagni E, et al. Factors associated with fertility abnormalities in women with systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2022;21(4):103038. DOI:10.1016/j.autrev.2022.103038
27. Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev. 2010;9(5):A277-87. DOI:10.1016/j.autrev.2009.12.008
28. Mok CC, Lau CS, Wong RW. Use of exogenous estrogens in systemic lupus erythematosus. Semin Arthritis Rheum. 2001;30(6):426-35. DOI:10.1053/sarh.2001.22498
29. Fernández M, Calvo-Alén J, Alarcón GS, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women. Arthritis Rheum. 2005;52(6):1655-64. DOI:10.1002/art.21048
30. Boddaert J, Huong DLT, Amoura Z, el al. Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine (Baltimore). 2004;83(6):348-59. DOI:10.1097/01.md.0000147737.57861.7c
31. Tomic-Lucic A, Petrovic R, Radak-Perovic M, et al. Late-onset systemic lupus erythematosus: clinical features, course, and prognosis. Clin Rheumatol. 2013;32(7):1053-8. DOI:10.1007/s10067-013-2238-y
32. Talsania M, Scofield RH. Menopause and Rheumatic Disease. Rheum Dis Clin North Am. 2017;43(2):287-302. DOI:10.1016/j.rdc.2016.12.011
33. Sanches-Guerrero J, Romero-Diaz J, Mendoza-Fuentes A, et al. Menopause in systemic lupus erythematosus. Age at menopause and clinical characteristics. Arthritis Rheum. 1999;42 Suppl. 9:205.
34. Mok CC, Lau CS, Ho CT, et al. Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus. Scand J Rheumatol. 1998;27(5):342-6. DOI:10.1080/0300974985015435
35. González LA, Pons-Estel GJ, Zhang JS, et al. Effect of age, menopause and cyclophosphamide use on damage accrual in systemic lupus erythematosus patients from LUMINA, a multiethnic US cohort (LUMINA LXIII). Lupus. 2009;18(2):184-6. DOI:10.1177/0961203308098988
36. Mayorga J, Alpízar-Rodríguez D, Prieto-Padilla J, et al. Prevalence of premature ovarian failure in patients with systemic lupus erythematosus. Lupus. 2016;25(7):675-83. DOI:10.1177/0961203315622824
37. Di Mario C, Petricca L, Gigante MR, et al. Anti-Müllerian hormone serum levels in systemic lupus erythematosus patients: Influence of the disease severity and therapy on the ovarian reserve. Endocrine. 2019;63(2):369-75. DOI:10.1007/s12020-018-1783-1
38. Alpízar-Rodríguez D, Romero-Díaz J, Sánchez-Guerrero J, et al. Age at natural menopause among patients with systemic lupus erythematosus. Rheumatology (Oxford). 2014;53(11):2023-9. DOI:10.1093/rheumatology/keu222
39. Lawrenz B, Henes J, Henes M, et al. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormone. Lupus. 2011;20(11):1193-7. DOI:10.1177/0961203311409272
40. Morel N, Bachelot A, Chakhtoura Z, et al. Study of anti-Müllerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol Metab. 2013;98(9):3785-92. DOI:10.1210/jc.2013-1235
41. Marder W, McCune WJ, Wang L, et al. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients. Gynecol Endocrinol. 2012;28(8):624-7. DOI:10.3109/09513590.2011.650752
42. Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 1998;41(5):831-7. DOI:10.1002/1529-0131(199805)41:5<831::AID-ART9>3.0.CO;2-1
43. Safiri S, Kolahi AA, Hoy D, et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019;78(11):1463-71. DOI:10.1136/annrheumdis-2019-215920
44. Prasad P, Verma S, Surbhi, et al. Rheumatoid arthritis: advances in treatment strategies. Mol Cell Biochem. 2023;478(1):69-88. DOI:10.1007/s11010-022-04492-3
45. Насонов Е.Л., Лила А.М., Каратеев Д.Е., и др. Ревматоидный артрит. Клинические рекомендации. М.: Ассоциация ревматологов России, Российская ревматологическая ассоциация «Надежда», 2021 [Nasonov EL, Lila AM, Karateyev DE, et al. Revmatoidnyi artrit. Klinicheskiie rekomendatsii. Moscow: Assotsiatsiia revmatologov Rossii, Rossiyskaia revmatologicheskaia assotsiatsiia “Nadezhda”, 2021 (in Russian)].
46. Brouwer J, Laven JS, Hazes JM, et al. Levels of serum anti-Müllerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013;65(9):1534-8. DOI:10.1002/acr.22013
47. Del Junco DJ, Annegers JF, Coulam CB, Luthra HS. The relationship between rheumatoid arthritis and reproductive function. Br J Rheumatol. 1989;28 Suppl. 1:33-45. DOI:10.1093/rheumatology/xxviii.suppl_1.33
48. Banas T, Hajdyla-Banas I, Pitynski K, et al. Age at natural menopause in women on long-term methotrexate therapy for rheumatoid arthritis. Menopause. 2016;23(10):1130-8. DOI:10.1097/GME.0000000000000674
49. Pikwer M, Nilsson JÅ, Bergström U, et al. Early menopause and severity of rheumatoid arthritis in women older than 45 years. Arthritis Res Ther. 2012;14(4):R190. DOI:10.1186/ar4021
50. Merlino LA, Cerhan JR, Criswell LA, et al. Estrogen and other female reproductive risk factors are not strongly associated with the development of rheumatoid arthritis in elderly women. Semin Arthritis Rheum. 2003;33(2):72-82. DOI:10.1016/s0049-0172(03)00084-2
51. Wong LE, Huang WT, Pope JE, et al. Effect of age at menopause on disease presentation in early rheumatoid arthritis: results from the Canadian Early Arthritis Cohort. Arthritis Care Res (Hoboken). 2015;67(5):616-23. DOI:10.1002/acr.22494
52. Pfeifer EC, Crowson CS, Amin S, et al. The influence of early menopause on cardiovascular risk in women with rheumatoid arthritis. J Rheumatol. 2014;41(7):1270-5. DOI:10.3899/jrheum.131234
53. Pikwer M, Bergström U, Nilsson JÅ, et al. Early menopause is an independent predictor of rheumatoid arthritis. Ann Rheum Dis. 2012;71(3):378-81. DOI:10.1136/ard.2011.200059
54. Beydoun HA, el-Amin R, McNeal M, et al. Reproductive history and postmenopausal rheumatoid arthritis among women 60 years or older: Third National Health and Nutrition Examination Survey. Menopause. 2013;20(9):930-5. DOI:10.1097/GME.0b013e3182a14372
55. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken).
2021;73(7):924-39. DOI:10.1002/acr.24596
56. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492-509. DOI:10.1136/annrheumdis-2013-204573
57. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14(5):1718-29. DOI:10.1200/JCO.1996.14.5.1718
58. Eudy AM, McDaniel G, Hurd WW, Clowse ME. Fertility and Ovarian Reserve among Women with Rheumatoid Arthritis. J Rheumatol. 2019;46(5):455-9. DOI:10.3899/jrheum.180176
59. Ананьева Л.П. Новые направления в лечении системной склеродермии (системного прогрессирующего склероза). Доктор. Ру. 2021;20(7):32-9 [Ananieva LP. New Approaches in Management of Generalized Scleroderma (Progressive Systemic Sclerosis). Doctor.Ru. 2021; 20(7):32-9 (in Russian)]. DOI:10.31550/1727-2378-2021-20-7-32-39
60. Ананьева Л.П. Лечение системной склеродермии с учетом национальных рекомендаций и рекомендаций Eвропейской лиги по борьбе с ревматизмом (EULAR). Фарматека. 2014;21(10):79-86 [Anan'ieva LP. Lecheniie sistemnoi sklerodermii s uchetom natsional'nykh rekomendatsii i rekomendatsii Evropeiskoi ligi po bor'be s revmatizmom (EULAR). Farmateka. 2014;21(10):79-86 (in Russian)].
61. Hughes M, Pauling J, Armstrong-James L, et al. Gender-related differences in systemic sclerosis. Autoimmun Rev. 2020;19:102494. DOI:10.1016/j.autrev.2020.102494
62. Bairkdar M, Rossides M, Westerlind H, et al. Incidence and prevalence of systemic sclerosis globally: A comprehensive systematic review and meta-analysis. Rheumatology. 2021;60:3121-33. DOI:10.1093/rheumatology/keab190
63. Kowalska-Kępczyńska A. Systemic Scleroderma-Definition, Clinical Picture and Laboratory Diagnostics. J Clin Med. 2022;11(9):2299. DOI:10.3390/jcm11092299
64. Sampaio-Barros PD, Samara AM, Marques Neto JF. Gynaecologic history in systemic sclerosis. Clin Rheumatol. 2000;19(3):184-7. DOI:10.1007/s100670050152
65. Адамян Л.В., Андреева Е.Н., Аполихина И.А., и др. Менопауза и климактерическое состояние у женщины. Клинические рекомендации. М.: Российское общество акушеров-гинекологов, 2021 [Adamian LV, Andreeva EN, Apolikhina IA, et al. Menopauza i klimaktericheskoie sostoianiie u zhenshchiny. Klinicheskiie rekomendatsii. Moscow: Rossiiskoie obshchestvo akusherov-ginekologov, 2021 (in Russian)].
66. La Montagna G, Vatti M, Valentini G, Tirri G. Osteopenia in systemic sclerosis. Evidence of a participating role of earlier menopause. Clin Rheumatol. 1991;10(1):18-22. DOI:10.1007/BF02208027
67. Bhadauria S, Moser DK, Clements PJ, et al. Genital tract abnormalities and female sexual function impairment in systemic sclerosis. Am J Obstet Gynecol. 1995;172(2 Pt. 1):580-7. DOI:10.1016/0002-9378(95)90576-6

________________________________________________

1. European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI; Webber L, Davies M, Anderson R, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926-37. DOI:10.1093/humrep/dew027
2. Adamyan LV, Pivazyan LG, Antonova AA. Autoimmunity and premature ovarian insufficiency – up-to-date. Russian Journal of Human Reproduction. 2022;28(6):116-24 (in Russian). DOI:10.17116/repro202228061116
3. Chon SJ, Umair Z, Yoon MS. Premature Ovarian Insufficiency: Past, Present, and Future. Front Cell Dev Biol. 2021;9:672890. DOI:10.3389/fcell.2021.672890
4. Adamian LV, Andreeva EN, Artymuk NV, et al. Amenoreia i oligomenoreia. Klinicheskiie rekomendatsii. Moscow: Rossiiskoie obshchestvo akusherov-ginekologov, 2021 (in Russian).
5. Kravchenko EN, Vorontsova MS. Premature ovarian insufficiency: modern view of the problem. Mat’ i ditia v Kuzbasse. 2022;88(1):4-10 (in Russian).
DOI:10.24412/2686-7338-2022-1-4-10
6. Ishizuka B. Current Understanding of the Etiology, Symptomatology, and Treatment Options in Premature Ovarian Insufficiency (POI). Front Endocrinol (Lausanne). 2021;12:626924. DOI:10.3389/fendo.2021.626924.
7. Christin-Maitre S, Givony M, Albarel F, et al. Position statement on the diagnosis and management of premature/primary ovarian insufficiency (except Turner Syndrome). Ann Endocrinol (Paris). 2021;82(6):555-71. DOI:10.1016/j.ando.2021.09.001.
8. Adamyan LV, Pivazyan LG. Interdisciplinary approach and the current state of the issue of premature ovarian aging (literature review). Russian Journal of Human Reproduction. 2023;29(1):94-103 (in Russian). DOI:10.17116/repro20232901194
9. Andreeva EN, Absatarova YS, Akhmatova RR, et al. Primary ovarian insufficiency: from basis of pathogenesis to treatment perspectives. Gynecology, Obstetrics and Perinatology. 2021;20(5):100-7 (in Russian). DOI:10.20953/1726-1678-2021-5-100-107
10. Forges T, Monnier-Barbarino P, Faure GC, Béné MC. Autoimmunity and antigenic targets in ovarian pathology. Hum Reprod Update. 2004;10(2):163-75. DOI:10.1093/humupd/dmh014
11. Domniz N, Meirow D. Premature ovarian insufficiency and autoimmune diseases. Best Pract Res Clin Obstet Gynaecol. 2019;60:42-55. DOI:10.1016/j.bpobgyn.2019.07.008.
12. Euthymiopoulou K, Aletras AJ, Ravazoula P, et al. Antiovarian antibodies in primary Sjogren's syndrome. Rheumatol Int. 2007;27(12):1149-55. DOI:10.1007/s00296-007-0364-z
13. Szeliga A, Calik-Ksepka A, Maciejewska-Jeske M, et al. Autoimmune Diseases in Patients with Premature Ovarian Insufficiency – Our Current State of Knowledge. Int J Mol Sci. 2021;22(5):2594. DOI:10.3390/ijms22052594
14. Panevin TS, Molashenko NV, Troshina EA, Golovenko EN. Autoimmune polyglandular syndrome of adults: current ideas about predictors development of damage of a myocardium and diagnostics of components of a disease. Clinical and Experimental Thyroidology. 2018;14(2):92-9 (in Russian). DOI:10.14341/ket9641
15. Zhen X, Qiao J, Li R, et al. Serologic autoimmunologic parameters in women with primary ovarian insufficiency. BMC Immunol. 2014;15:11. DOI:10.1186/1471-2172-15-11
16. Mignot MH, Schoemaker J, Kleingeld M, et al. Premature ovarian failure. I: The association with autoimmunity. Eur J Obstet Gynecol Reprod Biol. 1989;30(1):59-66. DOI:10.1016/0028-2243(89)90094-4
17. Vlasova GA, Perminova SG, Kosheleva NM, Veyukova MA. Impact of therapy for autoimmune rheumatic diseases on reproductive function. Obstetrics and Gynecology. 2021;7:53-60 (in Russian). DOI:10.18565/aig.2021.7.53-60
18. Perminova SG, Vlasova GA, Kosheleva NM. Reproductive function of women with rheumatoid arthritis: the effect of the disease and methotrexate therapy on the serum level of anti-Müllerian hormone. Obstetrics and Gynecology. 2020;4:104-10 (in Russian). DOI:10.18565/aig.2020.4.104-110
19. Alekberova ZS, Egorova ON, Goloeva RG, et al. Anti-Mullerian hormone in systemic lupus erythematosus. Modern Rheumatology Journal. 2021;15(1):105-10 (in Russian). DOI:10.14412/1996-7012-2021-1-105-110
20. Grossmann B, Saur S, Rall K, et al. Prevalence of autoimmune disease in women with premature ovarian failure. Eur J Contracept Reprod Health Care. 2020;25(1):72-5. DOI:10.1080/13625187.2019.1702638
21. Pasoto SG, Viana VS, Mendonca BB, et al. Anti-corpus luteum antibody: a novel serological marker for ovarian dysfunction in systemic lupus erythematosus? J Rheumatol. 1999;26(5):1087-93.
22. Karakus S, Sahin A, Durmaz Y, et al. Evaluation of ovarian reserve using anti-müllerian hormone and antral follicle count in Sjögren's syndrome: Preliminary study. J Obstet Gynaecol Res. 2017;43(2):303-7. DOI:10.1111/jog.13216
23. Henes M, Froeschlin J, Taran FA, et al. Ovarian reserve alterations in premenopausal women with chronic inflammatory rheumatic diseases: impact of rheumatoid arthritis, Behçet's disease and spondyloarthritis on anti-Müllerian hormone levels. Rheumatology (Oxford). 2015;54(9):1709-12. DOI:10.1093/rheumatology/kev124
24. Brouwer J, Dolhain RJ, Hazes JM, et al. Reduced Ovarian Function in Female Rheumatoid Arthritis Patients Trying to Conceive. ACR Open Rheumatol. 2019;1(5):327-35. DOI:10.1002/acr2.11043
25. Eudy AM, McDaniel G, Hurd WW, Clowse ME. Fertility and Ovarian Reserve among Women with Rheumatoid Arthritis. J Rheumatol. 2019;46(5):455-9. DOI:10.3899/jrheum.180176
26. Giambalvo S, Garaffoni C, Silvagni E, et al. Factors associated with fertility abnormalities in women with systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2022;21(4):103038. DOI:10.1016/j.autrev.2022.103038
27. Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev. 2010;9(5):A277-87. DOI:10.1016/j.autrev.2009.12.008
28. Mok CC, Lau CS, Wong RW. Use of exogenous estrogens in systemic lupus erythematosus. Semin Arthritis Rheum. 2001;30(6):426-35. DOI:10.1053/sarh.2001.22498
29. Fernández M, Calvo-Alén J, Alarcón GS, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women. Arthritis Rheum. 2005;52(6):1655-64. DOI:10.1002/art.21048
30. Boddaert J, Huong DLT, Amoura Z, el al. Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine (Baltimore). 2004;83(6):348-59. DOI:10.1097/01.md.0000147737.57861.7c
31. Tomic-Lucic A, Petrovic R, Radak-Perovic M, et al. Late-onset systemic lupus erythematosus: clinical features, course, and prognosis. Clin Rheumatol. 2013;32(7):1053-8. DOI:10.1007/s10067-013-2238-y
32. Talsania M, Scofield RH. Menopause and Rheumatic Disease. Rheum Dis Clin North Am. 2017;43(2):287-302. DOI:10.1016/j.rdc.2016.12.011
33. Sanches-Guerrero J, Romero-Diaz J, Mendoza-Fuentes A, et al. Menopause in systemic lupus erythematosus. Age at menopause and clinical characteristics. Arthritis Rheum. 1999;42 Suppl. 9:205.
34. Mok CC, Lau CS, Ho CT, et al. Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus. Scand J Rheumatol. 1998;27(5):342-6. DOI:10.1080/0300974985015435
35. González LA, Pons-Estel GJ, Zhang JS, et al. Effect of age, menopause and cyclophosphamide use on damage accrual in systemic lupus erythematosus patients from LUMINA, a multiethnic US cohort (LUMINA LXIII). Lupus. 2009;18(2):184-6. DOI:10.1177/0961203308098988
36. Mayorga J, Alpízar-Rodríguez D, Prieto-Padilla J, et al. Prevalence of premature ovarian failure in patients with systemic lupus erythematosus. Lupus. 2016;25(7):675-83. DOI:10.1177/0961203315622824
37. Di Mario C, Petricca L, Gigante MR, et al. Anti-Müllerian hormone serum levels in systemic lupus erythematosus patients: Influence of the disease severity and therapy on the ovarian reserve. Endocrine. 2019;63(2):369-75. DOI:10.1007/s12020-018-1783-1
38. Alpízar-Rodríguez D, Romero-Díaz J, Sánchez-Guerrero J, et al. Age at natural menopause among patients with systemic lupus erythematosus. Rheumatology (Oxford). 2014;53(11):2023-9. DOI:10.1093/rheumatology/keu222
39. Lawrenz B, Henes J, Henes M, et al. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormone. Lupus. 2011;20(11):1193-7. DOI:10.1177/0961203311409272
40. Morel N, Bachelot A, Chakhtoura Z, et al. Study of anti-Müllerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol Metab. 2013;98(9):3785-92. DOI:10.1210/jc.2013-1235
41. Marder W, McCune WJ, Wang L, et al. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients. Gynecol Endocrinol. 2012;28(8):624-7. DOI:10.3109/09513590.2011.650752
42. Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 1998;41(5):831-7. DOI:10.1002/1529-0131(199805)41:5<831::AID-ART9>3.0.CO;2-1
43. Safiri S, Kolahi AA, Hoy D, et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019;78(11):1463-71. DOI:10.1136/annrheumdis-2019-215920
44. Prasad P, Verma S, Surbhi, et al. Rheumatoid arthritis: advances in treatment strategies. Mol Cell Biochem. 2023;478(1):69-88. DOI:10.1007/s11010-022-04492-3
45. Nasonov EL, Lila AM, Karateyev DE, et al. Revmatoidnyi artrit. Klinicheskiie rekomendatsii. Moscow: Assotsiatsiia revmatologov Rossii, Rossiyskaia revmatologicheskaia assotsiatsiia “Nadezhda”, 2021 (in Russian).
46. Brouwer J, Laven JS, Hazes JM, et al. Levels of serum anti-Müllerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013;65(9):1534-8. DOI:10.1002/acr.22013
47. Del Junco DJ, Annegers JF, Coulam CB, Luthra HS. The relationship between rheumatoid arthritis and reproductive function. Br J Rheumatol. 1989;28 Suppl. 1:33-45. DOI:10.1093/rheumatology/xxviii.suppl_1.33
48. Banas T, Hajdyla-Banas I, Pitynski K, et al. Age at natural menopause in women on long-term methotrexate therapy for rheumatoid arthritis. Menopause. 2016;23(10):1130-8. DOI:10.1097/GME.0000000000000674
49. Pikwer M, Nilsson JÅ, Bergström U, et al. Early menopause and severity of rheumatoid arthritis in women older than 45 years. Arthritis Res Ther. 2012;14(4):R190. DOI:10.1186/ar4021
50. Merlino LA, Cerhan JR, Criswell LA, et al. Estrogen and other female reproductive risk factors are not strongly associated with the development of rheumatoid arthritis in elderly women. Semin Arthritis Rheum. 2003;33(2):72-82. DOI:10.1016/s0049-0172(03)00084-2
51. Wong LE, Huang WT, Pope JE, et al. Effect of age at menopause on disease presentation in early rheumatoid arthritis: results from the Canadian Early Arthritis Cohort. Arthritis Care Res (Hoboken). 2015;67(5):616-23. DOI:10.1002/acr.22494
52. Pfeifer EC, Crowson CS, Amin S, et al. The influence of early menopause on cardiovascular risk in women with rheumatoid arthritis. J Rheumatol. 2014;41(7):1270-5. DOI:10.3899/jrheum.131234
53. Pikwer M, Bergström U, Nilsson JÅ, et al. Early menopause is an independent predictor of rheumatoid arthritis. Ann Rheum Dis. 2012;71(3):378-81. DOI:10.1136/ard.2011.200059
54. Beydoun HA, el-Amin R, McNeal M, et al. Reproductive history and postmenopausal rheumatoid arthritis among women 60 years or older: Third National Health and Nutrition Examination Survey. Menopause. 2013;20(9):930-5. DOI:10.1097/GME.0b013e3182a14372
55. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken).
2021;73(7):924-39. DOI:10.1002/acr.24596
56. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492-509. DOI:10.1136/annrheumdis-2013-204573
57. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14(5):1718-29. DOI:10.1200/JCO.1996.14.5.1718
58. Eudy AM, McDaniel G, Hurd WW, Clowse ME. Fertility and Ovarian Reserve among Women with Rheumatoid Arthritis. J Rheumatol. 2019;46(5):455-9. DOI:10.3899/jrheum.180176
59. Ananieva LP. New Approaches in Management of Generalized Scleroderma (Progressive Systemic Sclerosis). Doctor.Ru. 2021; 20(7):32-9 (in Russian).
DOI:10.31550/1727-2378-2021-20-7-32-39
60. Anan'ieva LP. Lecheniie sistemnoi sklerodermii s uchetom natsional'nykh rekomendatsii i rekomendatsii Evropeiskoi ligi po bor'be s revmatizmom (EULAR). Farmateka. 2014;21(10):79-86 (in Russian).
61. Hughes M, Pauling J, Armstrong-James L, et al. Gender-related differences in systemic sclerosis. Autoimmun Rev. 2020;19:102494. DOI:10.1016/j.autrev.2020.102494
62. Bairkdar M, Rossides M, Westerlind H, et al. Incidence and prevalence of systemic sclerosis globally: A comprehensive systematic review and meta-analysis. Rheumatology. 2021;60:3121-33. DOI:10.1093/rheumatology/keab190
63. Kowalska-Kępczyńska A. Systemic Scleroderma-Definition, Clinical Picture and Laboratory Diagnostics. J Clin Med. 2022;11(9):2299. DOI:10.3390/jcm11092299
64. Sampaio-Barros PD, Samara AM, Marques Neto JF. Gynaecologic history in systemic sclerosis. Clin Rheumatol. 2000;19(3):184-7. DOI:10.1007/s100670050152
65. Adamian LV, Andreeva EN, Apolikhina IA, et al. Menopauza i klimaktericheskoie sostoianiie u zhenshchiny. Klinicheskiie rekomendatsii. Moscow: Rossiiskoie obshchestvo akusherov-ginekologov, 2021 (in Russian).
66. La Montagna G, Vatti M, Valentini G, Tirri G. Osteopenia in systemic sclerosis. Evidence of a participating role of earlier menopause. Clin Rheumatol. 1991;10(1):18-22. DOI:10.1007/BF02208027
67. Bhadauria S, Moser DK, Clements PJ, et al. Genital tract abnormalities and female sexual function impairment in systemic sclerosis. Am J Obstet Gynecol. 1995;172(2 Pt. 1):580-7. DOI:10.1016/0002-9378(95)90576-6

Авторы

Т.С. Паневин*^1,2, А.В. Ледина^3–5, Е.Г. Зоткин¹

¹ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия;
²ФГБОУ ВО «Дальневосточный государственный медицинский университет» Минздрава России, Хабаровск, Россия;
³ФГАОУ ВО «Российский университет дружбы народов», Москва, Россия;
⁴Общероссийская общественная организация «Российская ассоциация по генитальным инфекциям и неоплазии», Москва, Россия; 5Клинический госпиталь Лапино «Мать и дитя», д. Лапино, Россия
*tarasel@list.ru

________________________________________________

Taras S. Panevin*^1,2, Antonina V. Ledina^3–5, Evgeniy G. Zotkin¹

¹Nasonova Research Institute of Rheumatology, Moscow, Russia;
²Far-East State Medical University, Khabarovsk, Russia;
³People’s Friendship University of Russia (RUDN University), Moscow, Russia;
⁴Russian Association of Genital Infections and Neoplasia, Moscow, Russia; 5Lapino Clinical Hospital “Mother and Child”, Lapino, Russia
*tarasel@list.ru

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.